Objective-Transsignaling of interleukin (IL)-6 is a central pathway in the pathogenesis of disorders associated with chronic inflammation, such as Crohn disease, rheumatoid arthritis, and inflammatory colon cancer. Notably, IL-6 also represents an independent risk factor for coronary artery disease (CAD) in humans and is crucially involved in vascular inflammatory processes. Methods and Results-In the present study, we showed that treatment with a fusion protein of the natural IL-6 transsignaling inhibitor soluble glycoprotein 130 (sgp130) and IgG1-Fc (sgp130Fc) dramatically reduced atherosclerosis in hypercholesterolemic Ldlr Ϫ/Ϫ mice without affecting weight gain and serum lipid levels. Moreover, sgp130Fc treatment even led to a significant regression of advanced atherosclerosis. Mechanistically, endothelial activation and intimal smooth muscle cell infiltration were decreased in sgp130Fc-treated mice, resulting in a marked reduction of monocyte recruitment and subsequent atherosclerotic plaque progression. Of note, patients with CAD exhibited significantly lower plasma levels of endogenous sgp130, suggesting that a compromised counterbalancing of IL-6 transsignaling may contribute to atherogenesis in humans. Conclusion-These data clarify, for the first time, the critical involvement of, in particular, the transsignaling of IL-6 in CAD and warrant further investigation of sgp130Fc as a novel therapeutic for the treatment of CAD and related diseases.
A therosclerotic cardiovascular disease with its complications, such as acute myocardial infarction and stroke, is a major cause of morbidity and mortality in Western countries. It is well accepted that atherosclerosis is a chronic vascular inflammatory disease, mediated by a concerted action of the innate and the adaptive immunity. [1] [2] [3] [4] Inflammation defines the majority of mechanisms involved in atherosclerotic plaque development. 5 However, 70% of clinical events in patients with coronary artery disease (CAD) still cannot be prevented with modern drug therapy, including statins, emphasizing an urgent need for supplementary antiinflammatory treatment strategies. 6 Proinflammatory cytokines are central mediators of the chronic inflammatory process within the vascular wall. These cytokines, especially members of the interleukin (IL) family, contribute to endothelial activation by the induction of chemoattractant proteins, such as monocyte chemotactic protein-1, 7 and adhesion molecules, including vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1. 8, 9 Thereby, recruitment and infiltration of inflammatory cells into the subendothelium are initiated. Furthermore, cytokines trigger the release of matrix degrading proteases, chemokines, and reactive oxygen species, which accelerate atherosclerotic lesion progression. 4,10 -12 IL-6 is an important proinflammatory cytokine that has been identified as an independent risk factor for CAD 13, 14 and for which expression in human atherosclerotic plaques has already been demonstrated. 15 Sustained IL-6 production is involved in chronic low-level inflammation associated with obesity, which gives rise to insulin resistance and type 2 diabetes 16 and further promotes atherosclerosis. Moreover, convincing evidence from experimental studies points to a broad potential of IL-6 as a direct proatherosclerotic mediator. 17, 18 Accordingly, wild-type and atherosclerosis-prone Apoe Ϫ/Ϫ mice exhibit a dramatically increased lesion size when treated with recombinant IL-6 in addition to a high-fat diet. 19 To the contrary, complete IL-6-deficiency seems to be rather atheroprotective in both diet-and pathogen-associated atherosclerosis. 20 -23 Thus, the role of IL-6 in atherogenesis still remains to be determined.
As the signaling mechanism of IL-6 is quite complex, a systemic IL-6 deficiency might therefore not represent the optimal tool to unravel the diverse contributions of IL-6 to atherosclerosis. The so-called classic IL-6 signaling is initiated on binding of IL-6 to the membrane-bound IL-6 receptor (IL-6R) followed by subsequent complexation with the ubiquitously expressed coreceptor and signal transducer glycoprotein (gp) 130. 24 In addition, a process termed transsignaling has increasingly attracted attention in recent years. In IL-6 transsignaling, IL-6 binds to soluble forms of IL-6R (sIL-6R) and activates gp130. Whereas classic signaling is confined to restricted cell populations expressing the membrane-bound IL-6R, such as hepatocytes and certain leukocytes, transsignaling dramatically expands the range of potential target cells for IL-6 signaling. 17 Remarkably, recent studies revealed that IL-6 transsignaling, in particular, is crucially involved in chronic diseases with a clear inflammatory component, such as Crohn disease, rheumatoid arthritis, and inflammatory colon cancer. 25, 26 Soluble forms of gp130 (sgp130) are the natural inhibitors of IL-6 transsignaling and are present in molar excess in human plasma to prevent global transsignaling. To test the hypothesis that targeting IL-6 transsignaling can curtail the chronic vascular inflammation as pathophysiological basis of atherosclerosis, we used an optimized fusion protein of the natural sgp130 and IgG1-Fc. 27 This therapeutic fusion protein, called sgp130Fc, selectively inhibits IL-6 transsignaling by neutralizing IL-6/sIL-6R complexes without affecting classic signaling via the membranebound IL-6R. 27, 28 Our present study demonstrates that sgp130Fc treatment of atherosclerosis-prone Ldlr Ϫ/Ϫ mice on a high-fat, high-cholesterol diet resulted in a dramatic reduction of the atherosclerotic lesion formation and even led to a significant regression of advanced atherosclerosis. Moreover, patients with CAD exhibited significantly lower plasma levels of endogenous sgp130. These results underscore that IL-6 transsignaling, in particular, paves the way for atherogenesis and imply new therapeutic strategies for the treatment of this major health burden.
Methods

Animals
Male C57BL/6J Ldlr Ϫ/Ϫ (B6.129S7-Ldlr tm1Her /J) and C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained under pathogen-free conditions in the Central Animal Facility at Hannover Medical School. All experiments were approved by the governmental animal ethics committee and performed according to the guidelines of the Federation of European Animal Science Associations.
Treatment
The study was subdivided in 2 sections: (1) IL-6 transsignaling and atherogenesis and (2) IL-6 transsignaling and established atherosclerosis. (1) For the analysis of IL-6 transsignaling and atherogenesis (see Figure 2 ), Ldlr Ϫ/Ϫ mice at the age of 10 to 12 weeks were randomly assigned to 4 groups. All groups were fed a high-fat, high-cholesterol diet (D12108, Research Diets, New Brunswick, NJ); 2 group were intraperitoneally injected twice weekly with sgp130Fc (0.5 mg/kg body weight, CONARIS Research Institute, Kiel, Germany), whereas the control groups received only the vehicle phosphate-buffered saline (PBS, PAA Laboratories, Coelbe, Germany). Tissue and fasted plasma were collected from euthanized mice of the treatment and control group after 8 (nϭ5-7) and 16 (nϭ6 -9) weeks of diet, respectively. (2) For the analysis of IL-6 transsignaling and established atherosclerosis (see Figure 4 , with a graphical scheme of the study outline), Ldlr Ϫ/Ϫ mice at the age of 10 to 12 weeks were randomly assigned to 3 groups. All groups were fed the high-fat, high-cholesterol diet. Starting after 12 weeks of feeding, 1 group was intraperitoneally injected twice weekly with sgp130Fc (0.5 mg/kg body weight), whereas the control group received only the vehicle (PBS). Tissue and fasted plasma were collected from euthanized mice after 12 weeks of diet (baseline, nϭ7) and 24 weeks of diet, including 12 weeks with sgp130Fc injection (sgp130Fc, nϭ10) or with vehicle injection (control, nϭ8).
Statistical Analysis
All data are presented as the meanϮSEM or median with 25th/75th percentiles. After testing for normality and equal variance, data were compared using the 2-tailed Student t test for independent samples or 1-way ANOVA and a multiple comparison test when more than 2 groups were examined. When data were not normally distributed, the Mann-Whitney rank sum test or Kruskal-Wallis 1-way analysis of variance on ranks was applied as the nonparametric test (SigmaStat 3.0, Systat Software, Erkrath, Germany). A probability value of less than 0.05 was considered statistically significant.
For an expanded Methods section, see the supplemental materials, available online at http://atvb.ahajournals.org.
Results
Inhibition of Signal Transducer and Activator of Transcription 3 Phosphorylation by sgp130Fc In Vitro
The ability of sgp130Fc to specifically inhibit IL-6 transsignaling but not classic IL-6 signaling is already well documented. 28 However, little is known about the impact of sgp130Fc on IL-6-dependent signaling in cells crucially involved in atherogenesis. Therefore, we analyzed the activation of the key IL-6/gp130 signaling effector signal transducer and activator of transcription (STAT)3 in monocytic RAW 264.7 cells and primarily isolated endothelial cells, smooth muscle cells (SMCs), and CD3 ϩ T cells. These were compared with hepatocytes, which strongly express membrane-bound IL-6R. IL-6 induced a robust STAT3 phosphorylation in all cell types investigated, which was significantly suppressed by sgp130Fc application in RAW 264.7 cells (50 g/mL) and SMCs (10 g/mL) but not in hepatocytes, which only showed a trend toward lower STAT3 activity at 50 g/mL ( Figure 1A , 1C, and 1E). Of note, STAT3 phosphorylation in endothelial cells could not be activated by IL-6. Therefore, we used the IL-6/sIL-6R fusion protein hyper-IL-6, which exclusively activates IL-6 transsignaling via gp130 29, 30 and which induced a robust STAT3 phosphorylation (Supplemental Figure I) . However, hyper-IL-6-induced STAT3 activation in endothelial cells was already suppressed with 0.1 g/mL sgp130Fc and completely blunted with 10 g/mL sgp130Fc ( Figure 1B) . Similarly, STAT3 activation by IL-6 transsignaling in CD3 ϩ T cells was already suppressed with low doses of sgp130Fc ( Figure 1D ). STAT3 activation by other IL-6 cytokine family members, such as leukemia inhibitory factor or IL-11, was not impaired by sgp130Fc, emphasizing the specificity of sgp130Fc for IL-6 transsignaling (Supplemental Figure IIA 
Inhibition of IL-6 Transsignaling Attenuates Atherosclerotic Lesion Progression
The importance of IL-6 transsignaling for atherogenesis was investigated by comparing the atherosclerotic plaque development of hypercholesterolemic Ldlr Ϫ/Ϫ mice treated with sgp130Fc and Ldlr Ϫ/Ϫ control mice after 8 and 16 weeks of high-fat, high-cholesterol diet. As soon as after 8 weeks of diet, Ldlr Ϫ/Ϫ mice treated with sgp130Fc (0.5 mg/kg IP twice weekly) exhibited a markedly reduced lesion size in the aortic root, whereas only a slight decrease of the aortic lipid deposition was observed, as determined by Oil Red O staining (Figure 2A and 2B ). However, after 16 weeks of diet, sgp130Fc treatment led to an even more pronounced reduction of atherosclerotic plaque size in the aortic root and virtually arrested the increasing atherosclerotic burden in the thoracoabdominal aorta of hypercholesterolemic Ldlr Ϫ/Ϫ mice (Figure 2A and 2B). Of note, atherosclerosis in sgp130Fc-treated Ldlr Ϫ/Ϫ mice was significantly attenuated despite comparable weight gain (33.8Ϯ3.1 [control] versus 34.5Ϯ4.2 [sgp130Fc], meanϮSD, Pϭ0.7) and similar serum cholesterol and lipid levels compared with Ldlr Ϫ/Ϫ control mice ( Supplemental Table I ). Furthermore, sgp130Fc treatment did not exhibit adverse effects on blood pressure regulation or cardiac function as assessed by tail-cuff plethysmography and echocardiography (Supplemental Table II ).
In addition, we investigated specifically the vascular deposition of sgp130Fc in hypercholesterolemic mice. For this purpose, we analyzed en face preparations of aortas 6 hours after injection of DyLight-549-labeled sgp130Fc. We observed enrichment of the fluorescent dye not only in advanced highly Oil Red O-positive lesions but also in inflammation-prone areas surrounding vascular branches exposed to turbulent flow ( Figure 2C ). Importantly, the fluorescent dye moiety alone did not accumulate in the aortic wall in a nonspecific manner (Supplemental Figure IV). Using an antibody specific for the human Fc fragment of sgp130Fc, we observed the distribution of sgp130Fc into organs such as liver, spleen, and lymph nodes (Supplemental Figure V ) but also an abundant deposition in the vessel wall and in atherosclerotic plaques of the treatment group after 16 weeks of diet, whereas Ldlr Ϫ/Ϫ control mice did not show any staining ( Figure 2D ). Accordingly, STAT3 activation observed in plaques of Ldlr Ϫ/Ϫ control mice was clearly suppressed after 16 weeks of sgp130Fc treatment ( Figure 2E ). In contrast, activation of the nuclear factor B pathway, as reflected by the activity of the nuclear factor-B activator kinases inhibitor B kinase ␣ and inhibitor B kinase ␤, was not affected by sgp130Fc ( Figure 2F ). Pretreatment of C57Bl6/J mice with sgp130Fc inhibited short-term STAT3 phosphorylation in the aorta following IL-6 injection. The vascular nuclear factor-B system was neither activated by IL-6 nor affected by sgp130Fc treatment ( Figure 2G ). Similar to in vitro experiments with primarily isolated hepatocytes ( Figure 1D ), sgp130Fc did not block IL-6 induced STAT3 phosphorylation in the liver (Supplemental Figure V) . In addition, sgp130Fc did not affect plasma levels of major proinflammatory cytokines or soluble markers of endothelial activation. Neither IL-6 itself nor IL-1␤, tumor necrosis factor-␣, monocyte chemoattractant protein-1, sVCAM, and sICAM plasma levels of Ldlr Ϫ/Ϫ mice were significantly changed on sgp130Fc treatment for 8 and 16 weeks ( Supplemental Table III) . 
Inhibition of IL-6 Transsignaling Reduces Macrophage but Not CD3 ؉ T-Cell Infiltration Into the Plaque and Suppresses the Expression of Endothelial Adhesion Molecules
Next, we investigated how IL-6 transsignaling promotes atherosclerosis in a hypercholesterolemic environment. Because vascular inflammation with subsequent infiltration of macrophages into the vessel wall represents an initial step in the course of atherosclerosis, 5 we analyzed the effect of sgp130Fc treatment on IL-6-mediated macrophage recruitment. Remarkably, lesions of Ldlr Ϫ/Ϫ mice receiving sgp130Fc (0.5 mg/kg IP twice weekly) contained 30% fewer macrophages than Ldlr Ϫ/Ϫ control mice after 8 and 16 weeks of high-fat, high-cholesterol diet ( Figure 3A) . Consistently, we observed an enhanced migration of macrophage-like RAW 264.7 cells toward IL-6 in vitro, which was significantly inhibited after blocking of IL-6 transsignaling by sgp130Fc administration ( Figure 3B ). Endothelial activation with the expression of adhesion molecules plays a crucial role in the recruitment of inflammatory cells. 4 To elucidate whether sgp130Fc treatment could attenuate endothelial activation, we examined the early expression of 2 major endothelial adhesion molecules, VCAM-1 and ICAM-1, at atherosclerotic lesions in Ldlr Ϫ/Ϫ mice. Immunohistochemical analysis of the exceedingly atherosclerosis-susceptible aortic arch revealed an abundant endothelial VCAM-1 and ICAM-1 expression after 8 weeks of diet. In contrast, inhibition of IL-6 transsignaling by sgp130Fc treatment significantly diminished VCAM-1 and ICAM-1 expression ( Figure 3C and 3D) . Correspondingly, hyper-IL-6-induced upregulation of VCAM-1 and ICAM-1 expression was inhibited by sgp130Fc in isolated endothelial cells ( Figure 3E ).
Because T cells are also identified as important protagonists in the initiation and progression of atherosclerotic vascular disease, we likewise investigated the amount of T cells in the atherosclerotic lesion. Contrary to macrophages, we found significantly more T cells within and adjacent to atherosclerotic plaques in the aortic root of sgp130Fc-treated Ldlr Ϫ/Ϫ mice after 16 weeks of diet ( Figure 3F ). Interestingly, expression of Foxp3 mRNA-a marker of antiatherosclerotic acting T reg cells-was significantly enhanced on sgp130Fc treatment in the spleen, which is in line with a recent study demonstrating that IL-6 transsignaling suppresses the induction of T reg cells (Supplemental Figure VI) . However, we could not detect Foxp3 ϩ cells in the aortic roots in the experimental animals of our study.
Inhibition of IL-6 Transsignaling Reduces Advanced Atherosclerosis
To assess a therapeutic relevance for the inhibition of IL-6 transsignaling in preexisting atherosclerosis, we investigated the impact of sgp130Fc on already existing atherosclerotic plaques. To establish experimental atherosclerosis, we fed Ldlr Ϫ/Ϫ mice a high-fat, high-cholesterol diet for an initial period of 12 weeks (baseline). Subsequently, we continued this feeding for additional 12 weeks with vehicle (control) or with sgp130Fc (sgp130Fc; 0.5 mg/kg IP twice weekly) (graphical scheme of the study outline in Figure 4A ). Aortic lipid deposition and lesion size was determined by Oil Red O staining. Of note, we observed a marked reduction of thoracoabdominal lipid deposition in sgp130Fc treated mice (Figure 4B ). Analysis of aortic root lesion size even revealed a significant regression of experimental atherosclerosis under sgp130Fc treatment ( Figure 4C ).
Atherosclerotic Mice and Patients With CAD Have Lower Levels of Endogenous sgp130
As endogenous sgp130 also acts as a physiological inhibitor of IL-6 transsignaling, 28 we measured sgp130 plasma levels in atherosclerotic Ldlr Ϫ/Ϫ mice on a high-fat, high-cholesterol diet and in nonatherosclerotic Ldlr Ϫ/Ϫ control mice on a normal chow diet. We observed significantly lower levels of endogenous sgp130 in the plasma of atherosclerotic Ldlr Ϫ/Ϫ mice ( Figure 5A ). Differences in sgp130 plasma levels with respect to different periods of high-fat, high-cholesterol diet were not detected. In a translational approach, we measured sgp130 in plasma samples from 155 patients undergoing coronary angiography (for patient characteristics, see Supplemental Table IV ). Remarkably, patients with stable or unstable CAD exhibited significantly lower sgp130 levels as compared with control patients without CAD ( Figure 5B ). Of note, patients with unstable CAD with a 2-or 3-vessel CAD had even more reduced sgp130 level as compared with patients with unstable CAD and 1-vessel disease ( Figure 5C ). Especially unstable CAD patients exhibited increased IL-6 and decreased sIL-6R plasma levels. To assess the IL-6 transsignaling in particular, we calculated the IL-6/sIL-6R ratio, which was consequently enhanced in unstable patients ( Supplemental Table V) .
See supplemental materials for an expanded Results section demonstrating that (1) sgp130Fc did not influence hepatic effects of IL-6 in vivo, and (2) inhibition of IL-6 transsignaling by sgp130Fc delayed initial SMC infiltration in atherosclerosis-prone mice without any effects on collagen content in advanced plaques.
Discussion
In the present study, we demonstrate for the first time that selective pharmacological inhibition of IL-6 transsignaling using the fusion protein sgp130Fc significantly reduces the development and progression of atherosclerotic plaques even when atherosclerosis is already established. The antiatherosclerotic effect of sgp130Fc treatment was associated with a distinct decrease in the expression of endothelial adhesion molecules and consequently reduced macrophage infiltration into the vascular lesions. Additional mechanistic experiments confirmed that both hepatic IL-6 signaling in vitro and activation of the acute phase response in vivo were not impaired by sgp130Fc. Thus, sgp130Fc counteracted the adverse effects of hypercholesterolemia on vascular inflammation, resulting in a significant reduction of atherosclerotic burden without compromising hepatic IL-6 effects.
As a key inflammatory cytokine, IL-6 represents an independent risk factor for CAD in humans, and treatment with supraphysiological doses of IL-6 leads to accelerated atherosclerosis in mice. 13, 14, 19 However, studies from different groups using IL-6-deficient mice obtained conflicting results regarding the pathophysiological contribution of IL-6 to the course of atherosclerosis. 31 One major drawback of all these studies is the investigation of atherogenesis in a context of systemic, lifetime IL-6 deficiency, eliminating both classic IL-6 signaling and IL-6 transsignaling.
Of note, IL-6 has also physiological properties (eg, the acute phase response, regeneration of the epithelium in the intestine, and metabolic control in the liver) that are mediated predominantly by the classical IL-6 signaling via the membrane-bound IL-6R. 18, [32] [33] [34] In contrast, recent studies underscored that in all cases tested, proinflammatory functions of IL-6, such as recruitment of mononuclear cells or inhibition of regulatory T-cell differentiation, could be inhibited by sgp130Fc, which does not affect IL-6 responses via the membrane-bound IL-6R. 26 Thus, unspecific targeting of the IL-6 pathway in the therapy of chronic inflammatory diseases carries the risk of provoking serious side effects by suppressing not only the deleterious effects of IL-6, depending especially on the IL-6 transsignaling, but also the beneficial IL-6 functions mediated Supplemental Table IV. by the classical signaling. [35] [36] [37] Especially, the observed increase in serum cholesterol levels is a serious disadvantage in anti-inflammatory therapy (eg, for rheumatoid arthritis) with anti-IL-6R antibodies (tocilizumab), which enhances the cardiovascular risk and thereby renders this strategy ineligible for the long-term treatment of cardiovascular diseases. 38, 39 In contrast, sgp130Fc as the selective inhibitor of IL-6 transsignaling neither impeded acute phase response nor resulted in deteriorated lipid metabolism, thereby offering a drug profile more appropriate for the therapy of CAD. Furthermore, the inhibitory potency of sgp130Fc was very specific for IL-6 transsignaling, as the activity of other IL-6 cytokine family members, such as leukemia inhibitory factor and IL-11, was not inhibited by sgp130Fc. The onset of atherosclerosis is characterized by a loss of endothelial integrity accompanied by an inflammatory activation recruiting monocytes, in particular, into the subintimal space, which significantly contributes to the consecutive atherosclerotic lesion formation. 1, 4, 5 Recent studies have provided broad evidence that IL-6 is a central mediator of vascular inflammation: IL-6 promotes the expression of endothelial VCAM-1 and ICAM-1, as well as the secretion of chemoattractant proteins, such as monocyte chemoattractant protein-1, and it acts as a chemoattractant itself. 17, 18, 40, 41 We demonstrated a markedly attenuated endothelial expression of VCAM-1 and ICAM-1 in atherosclerotic Ldlr Ϫ/Ϫ mice treated with sgp130Fc. In addition, IL-6-induced upregulation of VCAM-1 and ICAM-1 was completely abolished by sgp130Fc in isolated endothelial cells. Moreover, the recruitment of monocytes into the vessel wall with subsequent differentiation into lipid-laden macrophage foam cells was consequently diminished under sgp130Fc therapy. This latter finding might be attributable not only to the reduced expression of endothelial adhesion molecules but also to the interference of sgp130Fc with the IL-6 induced migration of monocytic cells 41 that we observed in vitro.
With regard to the adaptive immunity, it has been revealed that IL-6 transsignaling effectively inhibits the induction of regulatory T cells, which are known to exert atheroprotective properties. 42, 43 In line with these data, we could demonstrate that the IL-6 transsignaling in T cells was markedly inhibited by sgp130Fc in vitro. Consequently, the extent of Foxp3 expression in the spleen as a central organ of the adaptive immunity was significantly increased on treatment with sgp130Fc in atherosclerotic mice. Therefore, it is tempting to speculate that atheroprotective and atheroregressive effects of sgp130Fc might also be mediated by a preserved induction of regulatory T cells. However, because of the low amount of this rare T-cell population, we were not able to detect Foxp3 ϩ cells in the aortic root of the experimental groups after 16 weeks of a high-cholesterol diet.
In addition to our results regarding vascular monocyte recruitment, SMCs likewise emerged to be sensitive to sgp130Fc treatment. Thus, IL-6-induced migration and proliferation of SMCs 18 -both processes that are assumed to be critical in early atherosclerosis 44 -were distinctly attenuated on transsignaling blockade by sgp130Fc in vitro. In vivo, we observed a significant reduction of SMCs within early atherosclerotic lesions in contrast to the initial increase of SMCs in the lesions of Ldlr Ϫ/Ϫ mice without sgp130Fc treatment. However, SMC content and collagen deposition in advanced lesions are not affected by sgp130Fc treatment (Supplemental Results and Supplemental Figure VI) . The fate of SMCs in atherogenesis, though, is still unsolved, and their functions appear rather controversial-stabilization in the cap region versus perpetuation of inflammation within the lesion. 44 -46 However, especially in the initial phase of atherogenesis, intimal SMCs are supposed to attract monocytes and macrophages via expression of cytokines and adhesion molecules and consecutively trap them in the vessel wall. 44 Therefore, the beneficial effects of IL-6 transsignaling blockade by sgp130Fc might be mainly attributable to the suppression of monocyte recruitment and macrophage retention and the subsequent striking prevention of atherosclerotic plaque formation.
Finally, IL-6 represents an independent risk factor for CAD and is abundantly found in human atherosclerotic plaques. 14, 15 As shown in the present study, patients with CAD-especially those in an unstable condition-exhibited enhanced IL-6 transsignaling and had significantly lower plasma levels of endogenous sgp130. Interestingly, sgp130 plasma levels even declined in proportion to advancing CAD. Because sgp130 is responsible for the adequate control of IL-6 transsignaling 35, 47 a link between increased IL-6 transsignaling and atherogenesis in humans can be proposed. sgp130Fc has been already successfully used to treat many murine disease models of different inflammatory conditions. In settings of high-level inflammation, sgp130Fc treatment ameliorated experimental colitis and inflammatory arthritis by suppression of STAT3-activation. 48, 49 Furthermore, sgp130Fc treatment was reported to abrogate inflammatory processes in a model of moderate local inflammation induced by injection of sterile air. 27 Last but not least, even chronic low-grade airway inflammation during allergic asthma was inhibited by sgp130Fc. 50 Of note, an optimized sgp130Fc variant is heading toward the first human studies in 2012. All this makes sgp130Fc a promising candidate for the treatment of experimental and severe human atherosclerosis.
In summary, our study demonstrates that IL-6 transsignaling is causally involved in the pathogenesis of atherosclerosis in mice and moreover potentially linked to atherogenesis in humans. Selective inhibition of IL-6 transsignaling by sgp130Fc resulted in an attenuated endothelial activation and a distinct decrease of atherosclerotic burden with lesions containing fewer macrophages and SMCs. Importantly, all this could be achieved without affecting the acute phase response, weight gain, or blood cholesterol levels (Supplemental Figure VIII ). Because these effects were independent of the prevailing hypercholesterolemia, we could underscore the importance of vascular inflammation in this context. Thus, targeting IL-6 transsignaling with sgp130Fc represents a promising approach for the treatment of atherosclerosis and prevention of life-threatening CAD.
